Acquired Company

Asahi Kasei completed the recommended public cash offer and became the owner of 93.30% of all Calliditas shares on September 2, 2024.

Calliditas Therapeutics AB (publ) is a clinical-stage biopharmaceutical firm based in Stockholm, specializing in the development of innovative therapies for orphan diseases, with a concentrated focus on kidney and liver disorders. The company boasts a robust pipeline poised to tackle significant unmet medical needs, reinforcing its commitment to scientific excellence and enhancing patient outcomes. Calliditas's strategic initiatives underscore its dedication to patient-centric solutions, making it an appealing investment prospect for institutional investors aiming to participate in the transformative healthcare landscape. Show more

Location: KUNGSBRON 1, D5, STOCKHOLM, SWEDEN, 111 22, Stockholm, 111 22, USA | Website: https://www.calliditas.se | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

1.097B

52 Wk Range

$0.00 - $0.00

Previous Close

$40.00

Open

$40.00

Volume

N/A

Day Range

$40.00 - $40.00

Enterprise Value

0.00

Cash

797.3M

Avg Qtr Burn

-7.043M

Insider Ownership

3.81%

Institutional Own.

0.32%

Qtr Updated

06/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TARPEYO (Nefecon) (budesonide) Details IgA nephropathy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TARPEYO (Nefecon) (budesonide) Details IgA nephropathy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Setanaxib Details Primary biliary cholangitis, Liver disease	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Setanaxib Details Alport Syndrome	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Setanaxib Details Idiopathic pulmonary fibrosis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Setanaxib Details Cancer, Solid tumor/s, Head and neck squamous cell carcinoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.